Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China

Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis

(2020) Jiaqi Han et al.   LUNG CANCER

Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer

(2020) Mohamed Ismail Abdul Aziz et al.   JOURNAL OF MEDICAL ECONOMICS

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

(2020) Naiyer A. Rizvi et al.   JAMA Oncology

Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer

(2020) Shen Lin et al.   International Journal of Clinical Pharmacy

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

(2020) Haiying Ding et al.   PLoS One

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

(2020) Huabin Hu et al.   Frontiers in Oncology

How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non–Small-Cell Lung Cancer

(2019) Solange Peters et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis

(2019) Sandjar Djalalov et al.   PHARMACOECONOMICS

Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis

(2019) Abdulaali R. Almutairi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores

(2019) Kexun Zhou et al.   LUNG CANCER

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases

(2019) Rui Kitadai et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in previously treated non-small cell lung cancer (NSCLC)

(2018) Ticiana A. Leal et al.   Journal of Thoracic Disease

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Hmwe Hmwe Kyu et al.   LANCET

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health state utilities in non-small cell lung cancer: An international study

(2016) Beenish Nafees et al.   Asia-Pacific Journal of Clinical Oncology

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

(2015) Bin Wu et al.   BMC CANCER

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line

(2014) Abdulaziz Al-Farsi et al.   Frontiers in Oncology

The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience

(2012) Xiaohui Zeng et al.   PLoS One

Improved curve fits to summary survival data: application to economic evaluation of health technologies

(2011) Martin W Hoyle et al.   BMC Medical Research Methodology